Trial · NCT03935646
Acute Effects of Stimulant Medication in College Students With ADHD
NCT03935646, Phase 2, Unknown, University of Wyoming
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acute Effects of Stimulant Medication in College Students With ADHD. Trials, record NCT03935646. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03935646
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acute Effects of Stimulant Medication in College Students With ADHD
- NCT number
- NCT03935646
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- University of Wyoming
- Conditions
- Attention Deficit Hyperactivity Disorder, Stimulant Use, Working Memory, Change in Sustained Attention, Mood
- Interventions
- Adderall IR 10mg, Placebo
- First posted
- 2019-05-02
- Last updated
- 2024-06-10
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Continuous Performance Test - Identical Pairs (CPT-IP) for Adderall vs. Placebo | Completed at baseline and each experimental appointment over a period of three weeks | The CPT-IP is a standardized computer-administered test consisting of four-digit numbers that are presented for 200ms on a white screen with 1500ms between the presentation of each number. Participants must press the spacebar as quickly as possible when the preceding four-digit number matches the current four-digit number. Participants will complete the CPT-IP as a measure of sustained attention at baseline and at each experimental appointment. |
| Primary | Change in Spatial Span (SS) for Adderall vs. Placebo | Completed at baseline and each experimental appointment over a period of three weeks | The Spatial Span (SS) is a computer-administered task assessing visuospatial working memory. Participants will be tasked with remembering the order of stimuli that are presented in forward and backward sequences. Participants will complete the SS visuospatial working memory task at baseline and at each experimental appointment. |
| Primary | Change in Digit Span for Adderall vs. Placebo | Completed at baseline and each experimental appointment over a period of three weeks | The Digit Span (Wechsler, 2008) subtest of the Wechsler Adult Intelligence Scale (WAIS-IV) is an auditory working memory task. The researcher will say numbers aloud at a rate of one number per second. The participant will be tasked with remembering and repeating the numbers in a prescribed (forward, backward, sequencing) order. Participants will complete the Digit Span (forward, backward and sequencing) auditory working memory task at baseline and at each experimental appointment. |
| Primary | Change in Letter-Number Sequencing for Adderall vs. Placebo | Completed at baseline and each experimental appointment over a period of three weeks | The Letter-Number Sequencing (Wechsler, 2008) task is a supplemental subtest of the Wechsler Adult Intelligence Scale (WAIS-IV) that measures auditory working memory. Researchers will read a sequence of letters and numbers, and the participant will attempt to recall the numbers in ascending order and the letters in alphabetical order. Participants will complete the Letter-Number Sequencing auditory working memory task at baseline and at each experimental appointment. |
| Primary | Visual Analogue Scales (VAS) for Adderall vs. Placebo | two weeks | The VAS is a nine-item questionnaire that assesses subjective mood in the moment including how good, bad, focused, and motivated participants feel. Additionally, participants are asked how well they expect to perform on cognitive tests and how much effort they will put into completing cognitive tests. Participants will complete the VAS at each experimental appointment. |
| Primary | Addiction Research Center Inventory (ARCI) for Adderall vs. Placebo | two weeks | The ARCI is a 49 true-false item measure that assesses drug effects by asking how the participant feels in the moment. Participants will complete the ARCI at each experimental appointment. |
| Primary | Intentions to Use Questionnaire (IUQ) for Adderall vs. Placebo | two weeks | The IUQ is a six-item measure that assesses the likelihood of participants to use substances including prescription stimulants for specific purposes such as for studying or improving academic performance. Participants will complete the IUQ at each experimental appointment. |
| Secondary | Pittsburgh Sleep Quality Index-Modified (PSQI-M) | Completed the day after each experimental appointment over a period of two weeks | The PSQI contains 19 items that evaluates several components of sleep quality by requiring participants to report their sleep behaviors. Participants will receive the survey via text and email the morning after their experimental appointment. They will be instructed to complete the PSQI-M regarding their sleep functioning (i.e., subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction) from "yesterday (from the time after your lab appointment until you went to bed)." |
| Secondary | Depression, Anxiety, and Stress Scale-Modified (DASS-M) | Completed the day after each experimental appointment over a period of two weeks | This scale includes 21 questions to measure current mood and stress levels. Items include a choice of four responses from "Did not apply to me at all," to "Applied to me very much." Participants will receive the survey via text and email the morning after their experimental appointment. They will be instructed to complete the DASS-M regarding their emotional experiences of depression, anxiety, and stress from "yesterday (from the time after your lab appointment until you went to bed)." |
| Secondary | DSM-5 ADHD Symptoms Checklist - Modified (DSM 5-M) | Completed the day after each experimental appointment over a period of two weeks | The DSM 5-M will ask participants about how often they experienced the symptoms of ADHD for the 24 hours from "yesterday (from the time after your lab appointment until you went to bed)" and will be completed following both experimental sessions |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Continuous Performance Test | Primary outcome | ConductCognition |
| Digit Span Test | Primary outcome | ConductCognition |
| Letter-Number Sequencing Task | Primary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03935646
GET https://conductscience.org/api/trials/v1/NCT03935646/registered